ProMIS Neurosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Shareholders' (Deficit) Equity

Consolidated Statements of Shareholders' (Deficit) Equity - USD ($)	Preferred Shares Series 2 preferred shares	Common Shares Series 2 preferred shares	Common Shares July 2024 Pipe Financing	Common Shares 2024 ATM offering	Common Shares 2025 ATM offering	Common Shares July 22, 2025 Exercise of Discounted Warrants And Pipe Offering	Common Shares July 28, 2025 Exercise of Discounted Warrants And Pipe Offering	Common Shares	Additional Paid-in Capital 2024 ATM offering	Additional Paid-in Capital 2025 ATM offering	Additional Paid-in Capital July 22, 2025 Exercise of Discounted Warrants And Pipe Offering	Additional Paid-in Capital July 28, 2025 Exercise of Discounted Warrants And Pipe Offering	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	2024 ATM offering	2025 ATM offering	July 22, 2025 Exercise of Discounted Warrants And Pipe Offering	July 28, 2025 Exercise of Discounted Warrants And Pipe Offering	Total
Balance at the beginning at Dec. 31, 2023													$ 97,590,426	$ (371,184)	$ (93,465,946)					$ 3,753,296
Balance at the beginning (in shares) at Dec. 31, 2023	46,667							755,362
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation													825,808							825,808
Conversion of Series 2 Convertible Preferred Shares (in shares)	(46,667)	46,667
Issuance of common shares, net of issuance costs									$ 190,274							$ 190,274
Issuance of common shares, net of issuance costs (in shares)			390,307	3,034												3,034
Exercise of pre-funded warrants													28,038							28,038
Exercise of pre-funded warrants (in shares)								112,150
Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency													8,689,148							8,689,148
Re-measurement of liability-classified CAD stock options													222,739							222,739
Net Income (Loss)															2,778,873					2,778,873
Balance at the end at Dec. 31, 2024													107,546,433	(371,184)	(90,687,073)					16,488,176
Balance at the end (in shares) at Dec. 31, 2024								1,307,520
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation													857,628							857,628
Issuance of common shares, net of issuance costs										$ 708,468							$ 708,468
Issuance of common shares, net of issuance costs (in shares)					40,795												40,795
Exercise of pre-funded warrants											$ 8,391,027	$ 11,144,467	3,050					$ 8,391,027	$ 11,144,467	$ 3,050
Exercise of pre-funded warrants (in shares)						336,449	416,436	51,197												51,197
Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency													697,658							$ 697,658
Re-measurement of liability-classified CAD stock options													170,081							170,081
Net Income (Loss)															(39,719,147)					(39,719,147)
Balance at the end at Dec. 31, 2025													$ 129,518,812	$ (371,184)	$ (130,406,220)					$ (1,258,592)
Balance at the end (in shares) at Dec. 31, 2025								2,152,397